Straits Times Index
3,330.81 +0.80 (+0.02%) S&P 500
5,349.45 -4.58 (-0.09%) Dow
38,881.77 +74.44 (+0.19%) Nasdaq
17,160.50 -27.41 (-0.16%) Bitcoin USD
70,687.92 -463.66 (-0.65%) CMC Crypto 200
1,516.66 -8.15 (-0.53%)
Molecular Partners AG (MOLN.SW)
| Previous close | 3.6700 |
| Open | 3.7000 |
| Bid | 3.6750 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.7000 - 3.9050 |
| 52-week range | 3.0400 - 6.1700 |
| Volume | |
| Avg. volume | 18,849 |
| Market cap | 124.433M |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose levelsWeekly and three-weekly dosing schedules established, supported by pharmacokinetics and pharmacodynamicsData support further clinical evaluation of MP0317 in combination settings ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Mo
- GlobeNewswire
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into IND-enabling studies with partner Orano Med, preclinical data to be presented at SNMMI 2024Switch-DARPin Platform: Initial data to be presented at EHA 2024; Preclinical proof-of-concept studies for c-KIT program planned for H2 2024MP0317: Final data from P
- GlobeNewswire
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cellsResults highlight MP0533-mediated T-cell activation and tumor regression, as well as cytokine release in AML models without systemic adverse effectsPublished data build on results previously presented at ASH 2021 and 2022, and support the rationale for the clinical development of MP0533 as monotherapy and in combination with azacitidine/venetoclaxOngo
